A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer
J Tabernero, M A Climent, A Lluch, J Albanell, J B Vermorken, A Barnadas, A Antón, C Laurent, J I Mayordomo, N Estaun, I Losa, V Guillem, J Garcia-Conde, J L Tisaire, J Baselga, J Tabernero, M A Climent, A Lluch, J Albanell, J B Vermorken, A Barnadas, A Antón, C Laurent, J I Mayordomo, N Estaun, I Losa, V Guillem, J Garcia-Conde, J L Tisaire, J Baselga
Abstract
Background: A phase II randomised trial was conducted to evaluate the tolerability and activity of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.
Patients and methods: Eighty-three patients with histologically proven metastatic breast cancer were randomised to receive either docetaxel 40 mg/m2 weekly for 6 consecutive weeks followed by 2 weeks without treatment (n = 41), or docetaxel 100 mg/m2 on day 1 every 3 weeks (n = 42).
Results: The incidence of all grade 3-4 adverse events was higher in the 3-weekly group than in the weekly group (96 versus 44), and the number of patients with grade 3-4 adverse events was also greater in the 3-weekly group (31 versus 20). Analysis of individual adverse events tended to favour the weekly regimen. Intent-to-treat overall response rate was 34% and 33% in the weekly and 3-weekly groups, respectively. Median time to progression was 5.7 and 5.3 months after weekly and 3-weekly docetaxel, respectively, and median time to treatment failure was 4.1 and 4.9 months, respectively.
Conclusion: Weekly docetaxel is an active regimen in metastatic breast cancer with comparable efficacy to 3 weekly docetaxel. Although both schedules were well tolerated, weekly docetaxel appears to have a more favourable toxicity profile.
Source: PubMed